BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Apr 25, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

LAX-101: Phase III data

Top-line data from the double-blind, U.S. Phase III ANCHOR trial in 702 patients with fasting triglyceride levels of 200-500 mg/dL who were also on background statin therapy showed that once-daily 2 and 4 g oral AMR101 for 12 weeks met the primary endpoint of significantly reducing triglycerides from baseline to week 12 vs. placebo. Specifically, low- and high-dose AMR101 led to median placebo-adjusted reductions in triglyceride levels of 10.1% and...

Read the full 329 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >